Talis Biomedical Corp reports results for the quarter ended in December - Earnings Summary

Talis Biomedical

16/03/2022 15:41

* Talis Biomedical Corp  TLIS.OQ  reported a quarterly
adjusted
loss of $1.26​​ per share for the quarter ended in December. The
mean expectation of three analysts for the quarter was for a
loss of $1.28 per share.
    * Revenue rose 268.2% to $858.00 thousand from a year ago; 
analysts expected $1.33 million. 
    * Talis Biomedical Corp's reported EPS for the quarter was a
loss
of $1.26​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Talis Biomedical Corp shares had fallen by 57.9% this
quarter.
    * The company reported a quarterly loss of $28.65 million.
    * Wall Street's median 12-month price target for Talis
Biomedical
Corp is $1.50 
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated March 16 at 03:41 p.m.  ​All
figures in US dollars unless otherwise stated